Lexicon’s Double Catalyst: HCM Enrollment Done, Zynquista NDA Resubmission on Deck

A de-risked SONATA-HCM plus a Zynquista regulatory resubmission that slipped to Q4 — but with a larger, more reassuring safety dataset.

LXRX · Earnings Call · 2026-08-06

A Quarter of Execution

Lexicon’s second-quarter call was defined by a single, decisive milestone: the completion of enrollment in SONATA HCM, the largest Phase III study in hypertrophic cardiomyopathy to date. CEO Michael Exton opened with the importance of the moment, noting the study was “significantly over-enrolled” and that top-line data remain on track for Q1 2027.

This marks an important milestone for patients living with the symptoms of HCM as SOTA would be a completely novel and complementary treatment for their disease…
Michael Exton, Chief Executive Officer and Director · 2026-08-06

The over-enrollment matters for more than optics. It strengthens statistical power for the primary endpoint, the KCCQ score at week 26, and gives the company greater confidence in a broad label. Management was careful to frame the patient mix as a feature, not a bug. The trial enrolled a substantial majority of symptomatic HCM patients with non-obstructive disease, a group with no approved therapy, while retaining a meaningful obstructive cohort. That positions sotagliflozin’s dual SGLT1/2 mechanism as a potential first-line option across the disease spectrum, both as monotherapy and in combination with cardiac myosin inhibitors.

Zynquista: A Slight Delay, a More Complete Package

The more nuanced update concerned Zynquista (sotagliflozin) in type 1 diabetes. The FDA’s three requirements for NDA resubmission — a prospective study, adequate patient exposure, and DKA rates below prior trials — are now near-satisfied, according to management. The open-label STENO1 study is expected to hit required exposure levels by the end of August, and DKA rates are tracking similar to standard of care. “STENO1 is on the verge of achieving the exposure levels previously identified by FDA as necessary to support a resubmission…” — Craig Granowitz, Senior Vice President and Chief Medical Officer · 2026-08-06 But the resubmission timeline has slipped. Prior guidance (March 2026) had anticipated approval before the end of 2026:

We expect a submission this year and as well an approval before the end of 2026.
Michael S. Exton, Chief Executive Officer and Director · 2026-03-05

Now, the company expects to resubmit in Q4 2026, with a six-month review clock pushing potential approval to mid-2027. The delay is attributed to data formatting and transfer from STENO, not to any safety concern. Management emphasized that the dataset is nearly as large as the entire inTandem program — a substantive body of real-world evidence to support the filing. “We believe that each of the FDA's criteria for resubmission of the NDA will soon be satisfied.” — Craig Granowitz, Senior Vice President and Chief Medical Officer · 2026-08-06

Financial Runway and the Road Ahead

Total revenue swung to $0.7M in Q2 2026 from $28.9M a year earlier, the prior figure having been boosted by $27.5M in Novo Nordisk licensing revenue. Net loss was $31.8M, inclusive of a $4.3M loss on early debt extinguishment. The balance sheet is the more important story: cash and short-term investments stood at $190.6M, strengthened by the February capital raise and a new $100M Hercules facility. CFO Scott Coiante noted the intent to preserve flexibility: “We have strengthened our balance sheet and improved our financial flexibility while remaining prudent with our expenses.” — Scott Coiante, Senior Vice President and Chief Financial Officer · 2026-08-06 Operating expense guidance for 2026 remains at $100–$110M, with targeted pre-commercial investments ahead of the expected 2027 data and launch. The strong benefit risk profile narrative that has carried through prior calls remains intact, reinforced by the DKA data and a clean safety record across thousands of patients. The stock has responded — up ~34% over the last 90 days, though it remains well below its 2012 peak. The next 12 months are loaded with catalysts: HCM top-line data in Q1 2027, Zynquista resubmission in Q4 2026, potential approval and launch in 2027, plus continued progress on LX9851 with Novo and international regulatory filings via Viatris. The company appears to be transitioning from a story of potential to one of near-term execution.